No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PTAB Invalidates 9 Johns Hopkins US Pembrolizumab Patents in MSD IPRs
Between 28 October 2025 and 17 November 2025, the US Patent Trial and Appeal Board (PTAB) issued final decisions invalidating Johns Hopkins University’s (JHU’s) 10,934,356 (IPR2024-00622), 11,325,974 (IPR2024-00623), 11,325,975 (IPR2024-00624) and 11,643,462 (IPR2024-00648) in four inter partes review proceedings (IPRs) brought by MSD.